ArticleBMC cancer2026
Smoking metabolic signature modifies the risk of colorectal cancer and interacts with genetic susceptibility: a large-scale prospective cohort study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSmoking tobacco is proven to be associated with higher colorectal cancer (CRC) risk. However, the metabolic pathways of smoking and how they relate to CRC risk are unclear.
methodsA total of 227,898 participants from the UK Biobank were included. A two-stage strategy with a combination of linear regression and Mendelian randomization analysis was employed to identify smoking-related metabolites. Then the elastic net (EN) regression model was used to construct smoking-related metabolic signature. Multivariable Cox regression, Mediation analysis, and interaction analysis were employed to illustrate the associations of smoking and smoking related metabolic signature on the risk of CRC. Furthermore, the interaction between genetic susceptibility and smoking metabolic signature was estimated based on relative excess risk due to interaction (RERI) and multiplicative-scale interaction.
resultsDuring a follow-up of 12.5 years, 3,328 incident CRC patients were observed. We identified 71 smoking-related metabolites and screened 42 of them metabolites by EN model to construct smoking-related metabolic signature. We observed smoking and smoking metabolic signature were both associated with the elevated risk of CRC, with a hazard ratio (HR) value of 1.27 and 1.38, respectively. Mediation analysis revealed metabolic signature can mediate 10.03% in the association between smoking and CRC risk. The additive interaction between genetic susceptibility and metabolic signature was statistically significant (RERI = 0.70, 95% confidence interval [CI] = 0.29-1.10).
conclusionThe detrimental impact of smoking on CRC risk is mediated partially by smoking metabolic signature, which is synergistic with genetic susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.